Abstract:Objective To investigate the changes of serine protease 1 (HTRA1) in gastric cancer patients and the influencing factors.Methods A total of 220 patients with gastric cancer clinically diagnosed in our hospital from July 2016 to July 2019 were selected as study objects.The expression of HTRA1 in gastric cancer and distant cancer was detected by immunohistochemistry, and the relationship between HTRA1 expression and clinical characteristics of gastric cancer was analyzed.Results The positive expression rate of HTRA1 protein in gastric cancer tissues (13.18%) was lower than that in distant cancer tissues (86.82%), the difference was statistically significant (P>0.05).The differences in tumor diameter, invasion depth, smoking history, drinking history and mental state between positive and negative HTRA1 protein expression patients were statistically significant (P<0.05), while the difference in age, gender, tissue differentiation degree, lymph node metastasis and TNM stage between positive and negative HTRA1 protein expression patients were not statistically significant (P>0.05).Logistic regression analysis showed that tumor diameter (β=0.532,OR=1.873, 95%CI 0.372-2.711), invasion depth (β=0.837, OR=1.103, 95%CI 0.822-2.014), smoking history (β=0.486,OR=1.569, 95%CI 1.023-2.832), drinking history (β=0.590, OR=1.690, 95%CI 0.934-3.721) and mental state (β=0.829, OR=1.552, 95%CI 1.032-2.831) were independent risk factors affecting gastric cancer (P<0.05).Conclusion HRA1 protein expression in gastric cancer is related to tumor diameter, invasion depth, smoking history, drinking history and mental state.Tumor diameter, invasion depth, smoking history, drinking history and mental state are all risk factors affecting gastric cancer.
江强. 丝氨酸蛋白酶1在胃癌组织中的表达及其影响因素分析[J]. 中国当代医药, 2020, 27(11): 173-175转186.
JIANG Qiang. Expression of serine protease 1 in gastric cancer and its influencing factors. 中国当代医药, 2020, 27(11): 173-175转186.
Yang D,Kotzev AI,Draganov PV.Endoscopic submucosal dissection for early gastric cancer in the west:the absolute but not final word[J].Gastrointest Endosc,2019,90(3):480-482.
Tan MC,Graham DY.Gastric cancer risk stratification and surveillance after Helicobacter pylori eradication:2020[J].Gastrointest Endosc,2019 ,90(3):457-460.
Tazawa H,Suzuki T,Komo T,et al.A Case of advanced gastric cancer with peritoneal metastasis treated successfully with nivolumab[J].Case Rep Oncol,2019,12(2):523-528.
[11]
Wu X,Wang H,Wu Y,et al.Efficacy of apatinib on multiple advanced-stage nongastric cancers[J].J Cancer Res Ther,2019,15(4):836-841.
[13]
Gao S,Cao GH,Ding P,et al.Retrospective evaluation of lymphatic and blood vessel invasion and Borrmann types in advanced proximal gastric cancer[J].World J Gastrointest Oncol,2019,11(8):642-651.
[15]
Basso V,Orry D,Fraisse J,et al.Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer:a retrospective study[J].World J Gastrointest Oncol,2019,11(8):634-641.
[16]
Pan HM,Lang WY,Yao LJ,et al.shRNA-interfering LSD1 inhibits proliferation and invasion of gastric cancer cells via VEGF-C/PI3K/AKT signaling pathway[J].World J Gastrointest Oncol,2019,11(8):622-633.
Yang L,Yu Y,Zhang Q,et al.Anti-gastric cancer effect of Salidroside through elevating miR-99a expression[J].Artif Cells Nanomed Biotechnol,2019,47(1):3500-3510.